低剂量肠溶与咀嚼阿司匹林在全膝和全髋关节置换术中预防静脉血栓栓塞的效果不等
本研究为回顾性单机构队列研究,纳入2017至2021年行初次全髋关节置换术(THA)和全膝关节置换术(TKA)的患者,比较咀嚼型非包衣阿司匹林81 mg组(4844例)与肠溶阿司匹林81 mg组(4388例)每日两次预防静脉血栓栓塞(VTE)的效果。结果显示,在THA和TKA合并分析及单纯THA患者中,两组术后VTE和胃肠道并发症发生率无显著差异;但在单纯TKA患者中,咀嚼型阿司匹林组VTE发生率显著低于肠溶组(0.22% vs 0.62%,P=0.037),胃肠道并发症无差异。作者认为在初次TKA中肠溶型低剂量阿司匹林预防VTE劣于咀嚼型,在THA中则不劣,两者胃肠道并发症相似,因此考虑从肠溶型转向非包衣咀嚼型低剂量阿司匹林是合理的。
要点
- 在THA和TKA合并分析中,咀嚼型与肠溶型阿司匹林组术后VTE(0.31% vs 0.55%,P=0.111)和胃肠道并发症(0.14% vs 0.14%,P=1.000)无显著差异。
- 在单纯TKA患者中,咀嚼型阿司匹林组VTE发生率显著低于肠溶组(0.22% vs 0.62%,P=0.037),胃肠道并发症无差异(0.13% vs 0.19%,P=0.277)。
- 在单纯THA患者中,两种剂型阿司匹林的VTE和胃肠道并发症发生率均无显著差异。
核心结论
- 在初次TKA中,肠溶型低剂量阿司匹林预防VTE劣于咀嚼型阿司匹林,但在THA患者中不劣。
- 两种剂型的胃肠道并发症发生率相似。
- 作者认为,考虑从肠溶型转向非包衣咀嚼型低剂量阿司匹林是合理的。
研究设计与样本
- 回顾性单机构队列研究,纳入2017至2021年行初次全髋关节置换术(THA)和全膝关节置换术(TKA)的患者。
- 咀嚼型非包衣阿司匹林81 mg组4844例,肠溶阿司匹林81 mg组4388例,均为每日两次。
- 功效分析显示,为达到80%功效,90天VTE率(劣效性检验)和胃肠道并发症(优效性检验)分别需要每组1978例和3686例患者。
- 两组基线特征相似,统计分析采用t检验和卡方检验,统计学显著性定义为P值<0.05。
主要发现
- 在THA和TKA合并分析中,术后VTE发生率咀嚼型组0.31% vs 肠溶组0.55%(P=0.111),胃肠道并发症发生率咀嚼型组0.14% vs 肠溶组0.14%(P=1.000),均无显著差异。
- 在单纯THA患者中,两种剂型的VTE和胃肠道并发症发生率均无显著差异。
- 在单纯TKA患者中,咀嚼型阿司匹林组VTE发生率显著低于肠溶组(0.22% vs 0.62%,P=0.037),胃肠道并发症发生率两组无差异(0.13% vs 0.19%,P=0.277)。
关键数值与推荐
- 咀嚼型非包衣阿司匹林81 mg每日两次与肠溶阿司匹林81 mg每日两次的比较。
- 主要结局为术后VTE和胃肠道并发症发生率。
- 统计学显著性定义为P值<0.05。
临床怎么用
- 作者认为,考虑从肠溶型转向非包衣咀嚼型低剂量阿司匹林是合理的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose aspirin is an effective venous thromboembolism (VTE) prophylactic medication in primary total joint arthroplasty, but the efficacy and safety of the formulations of chewable and enteric-coated aspirin have not been compared. The purpose of this study was to investigate the VTE and gastrointestinal (GI) complication rates of chewable and enteric-coated 81 mg aspirin bis in die for VTE prophylaxis in primary total joint arthroplasty. METHODS: A retrospective, single-institution cohort study was performed on patients who underwent primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) from 2017 to 2021. Comparisons were made between 4,844 patients who received chewable, noncoated aspirin 81 mg and 4,388 patients who received enteric-coated 81 mg aspirin. Power analysis demonstrated 1,978 and 3,686 patients were needed per group to achieve a power of 80% for 90-day VTE rates (using inferiority testing) and GI complications (using superiority testing), respectively. Patients had similar baseline characteristics. Statistical analyses were done using t-tests and Chi-squared tests, with statistical significance defined as a P value < .05. RESULTS: There were no significant differences in the incidences of postoperative VTE (0.31% versus 0.55%; P = .111) or GI complications (0.14% versus 0.14%; P = 1.000) between patients who received either chewable or enteric-coated 81 mg aspirin bis in die in the overall comparison that included both THA and TKA patients combined, or THA patients alone. However, the VTE incidence for TKA patients alone was significantly lower with chewable than enteric-coated aspirin (0.22% versus 0.62%; P = .037), with no difference in GI complications (0.13% versus 0.19%; P = .277). CONCLUSIONS: Low-dose aspirin in enteric-coated formulation is inferior to chewable aspirin for VTE prophylaxis in primary TKA, but not inferior in THA patients. Both formulations have a similar GI complication rate. Therefore, it is reasonable to consider a transition from enteric-coated to uncoated chewable low-dose aspirin.
引用
- D'Amore T, Cozzarelli NF, Sutton R, et al. Low-Dose Enteric-Coated and Chewable Aspirin Are Not Equally Effective in Preventing Venous Thromboembolism in Total Knee and Hip Arthroplasty. J Arthroplasty. 2024. PMID: 38889809. doi:10.1016/j.arth.2024.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。